Capricor TherapeuticsCAPR just hit that mark, with a jump from 69 to 86 Thursday. Please watch the video at Investors.com - ...

Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Fintel reports that on June 26, 2025, B. Riley Securities initiated coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a ...

Capricor Therapeutics updates on Deramiocel BLA for duchenne muscular dystrophy: San Diego Thursday, June 26, 2025, 15:30 Hrs [IST] Capricor Therapeutics, a biotechnology company ...

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on Longeveron (LGVN – Research Report) today and set a price target of $10.00. The company’s shares closed yeste ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

Capricor Therapeutics said on Tuesday the U.S. Food and Drug Administration will not convene its panel of outside experts before deciding on the company's cell therapy for a heart condition associated ...

Capricor Therapeutics shares climbed Tuesday after the Food and Drug Administration said an advisory committee meeting is not required before deciding on the company's cell therapy treatment for a ...